DUD OF ALL TIME

Quote

Anonymous

Guest
Its been several months since new management has taken over and sales continue to stagnate. The writing is on the wall. Qsymia is beyond a DUD. This isn't a management or a sales personnel issue. We just have a drug that is being rejected by its gatekeepers. Oh well. Good Luck to all and your professional careers. I am sure Qsymia will be around; whether Vivus exists in its present form is another issue.
 






Anonymous said:
Its been several months since new management has taken over and sales continue to stagnate. The writing is on the wall. Qsymia is beyond a DUD. This isn't a management or a sales personnel issue. We just have a drug that is being rejected by its gatekeepers. Oh well. Good Luck to all and your professional careers. I am sure Qsymia will be around; whether Vivus exists in its present form is another issue.
Click to expand...

With all of the post approval trials that Qsymia is required to do and how costly they are, I am not sure Qsymia will be around. I am not sure why anyone would take on all of that cost with very little income.
 






The approximate cost is $250 million for the trials. Maybe higher now since they are working to include the requirements for European Approval.

There is value to Qsymia. How much I don't know. If they could just get some traction beyond the 9K-11K weekly scripts the market may become a bit more positive on the value.
 


















Qsymia may not be the dud of all time. If Vivus strikes a deal with a larger pharma company things may work out. Not that their reps are any better, but their foot print will be larger. I would bet that any deal would require an upfront payment to offset most of the cost of the post trials for Qsymia. If that happens watch out!!! This will reinvigorate the company and create a laser focus on sales and insurance coverage.
 






Top Bottom
Back
Quote